Karthick Vishwanathan

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Geoffrey R. Oxnard, J.C.-H. Yang, Helena A. Yu et al. · Annals of Oncology · 2020 · 444 citations · Full text

Medicine, Oncology, Pharmacology +14

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

James Chih‐Hsin Yang, Sang-We Kim, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2019 · 397 citations · Full text

Medicine, Oncology, Pharmacology +17

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis

Myung‐Ju Ahn, Chao‐Hua Chiu, Ying Cheng et al. · Journal of Thoracic Oncology · 2019 · 169 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer

Kathryn H. Brown, Craig Comisar, Han Witjes et al. · British Journal of Clinical Pharmacology · 2016 · 147 citations · Full text

Medicine, Oncology, Pharmacology +13

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

David Planchard, Kathryn H. Brown, Dong‐Wan Kim et al. · Cancer Chemotherapy and Pharmacology · 2016 · 144 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +12